Complex regional pain syndrome (CRPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Indication name: Complex regional pain syndrome (CRPS)

Complex regional pain syndrome (CRPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030 (Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan & China)

Complex regional pain syndrome (CRPS) is a condition of intense burning pain, stiffness, swelling, and discoloration that most often affects the hand. Most CRPS is caused by damage to, or dysfunction of, injured peripheral sensory neurons, which then has secondary effects on the spinal cord and brain. In more than 90 percent of cases, CRPS is triggered by nerve trauma or injury to the affected limb that damages the thinnest sensory and autonomic nerve fibers.

CRPS can be classified in 2 types, Type 1 (reflex sympathetic dystrophy) occurs after an illness or injury that did not directly damage a nerve in the affected area. Type 2 (causalgia) follows a distinct nerve injury.

According to Thelansis estimates, CRPS occurs most frequently in people of European ancestry (in about 66 to 80 percent of cases). In the US, CRPS type I developed in 5.46 persons out of every 100,000 per year. It is estimated that CRPS affects nearly 200,000 patients annually in the United States.

Competitive landscape of Complex regional pain syndrome CRPS includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of Complex regional pain syndrome (CRPS) across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

Complex regional pain syndrome (CRPS) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Complex regional pain syndrome (CRPS) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

S. No        Asset        Company           Stage

1        Neridronic acid  Grünenthal GmbH         Phase 3

2        TAK-935        Millennium Pharmaceuticals, Inc.        Phase 2

3        AXS-02 (oral zoledronate)        Axsome Therapeutics, Inc.        Phase 3

4        Lenalidomide        Celgene Corporation        Phase 2

5        Fentanyl        Janssen Pharmaceutical K.K.        Phase 3

6        ketamine        iX Biopharma Ltd        Phase 3